{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T14:25:20Z","timestamp":1775917520389,"version":"3.50.1"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Pharm."],"abstract":"<jats:p>Oral anticoagulants, including warfarin, a vitamin K antagonist, have been used for anticoagulation therapy, but their limitations, such as drug interactions and complex dosing, have prompted the development of direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, dabigatran, and edoxaban. This study reviews the interactions of both warfarin and DOACs, particularly those influenced by cytochrome P450 enzymes and P-glycoprotein. Warfarin is metabolized by various cytochrome P450 isoforms, making it vulnerable to interactions with medications and herbs that modulate these enzymes. In contrast, DOACs, while having fewer interactions, are still affected by strong inducers or inhibitors of cytochrome 3A4 and P-glycoprotein, depending on the specific drug. Some herbs may also interfere with these pathways. Continuous monitoring of these interactions is crucial to ensure the safe use of oral anticoagulants. The findings underscore the importance of identifying and understanding these interactions to improve patient safety and guide appropriate anticoagulant therapy.<\/jats:p>","DOI":"10.3390\/scipharm93030035","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:27Z","timestamp":1753891767000},"page":"35","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risks of Oral Anticoagulants: Interactions with Drugs and Medicinal Plants"],"prefix":"10.3390","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5597-2269","authenticated-orcid":false,"given":"Ana Sofia","family":"Martins","sequence":"first","affiliation":[{"name":"Health Sciences Faculty, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"Public Health Unit, Local Health Unit of Guarda, 6301-857 Guarda, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5225-6222","authenticated-orcid":false,"given":"Cristina","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Health Sciences Faculty, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"UFBI-Pharmacovigilance Unit of Beira Interior, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3333-5977","authenticated-orcid":false,"given":"Ana Paula","family":"Duarte","sequence":"additional","affiliation":[{"name":"Health Sciences Faculty, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"UFBI-Pharmacovigilance Unit of Beira Interior, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Intera\u00e7\u00f5es Medicamentosas Potenciais em Farm\u00e1cia Comunit\u00e1ria-Estudo Explorat\u00f3rio","volume":"11","author":"Oliveira","year":"2022","journal-title":"Acta Farm. Port."},{"key":"ref_2","unstructured":"(2024, July 11). Revista De Fitoterapia. Published 2009. Available online: https:\/\/www.fitoterapia.net\/php\/descargar_documento.php?id=4523&doc_r=sn&num_volumen=22&secc_volumen=5959."},{"key":"ref_3","unstructured":"(2024, July 11). OIPM\u2014Observat\u00f3rio De Intera\u00e7\u00f5es Planta-Medicamento. Available online: http:\/\/www.oipm.uc.pt\/interacoes\/."},{"key":"ref_4","unstructured":"(2024, July 13). Ordem Dos Farmac\u00eauticos Podemos Minimizar O Risco De Intera\u00e7\u00f5es Medicamentosas?. Published 2021., Available online: https:\/\/www.ordemfarmaceuticos.pt\/pt\/artigos\/podemos-minimizar-o-risco-de-interacoes-medicamentosas\/."},{"key":"ref_5","unstructured":"Jandu, J.S., Mohanaselvan, A., Dahal, R., and Bista, S. (2025, July 07). Strategies to Reduce Polypharmacy in Older Adults, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574550\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/0975-1483.66807","article-title":"Drug interaction and pharmacist","volume":"2","author":"Ansari","year":"2010","journal-title":"J. Young Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pec.2011.04.038","article-title":"Mixed methods evaluation: Pharmacists\u2019 experiences and beliefs toward an interactive communication approach to patient interactions","volume":"83","author":"Guirguis","year":"2011","journal-title":"Patient Educ. Couns."},{"key":"ref_8","unstructured":"(2019). The ESC Handbook on Cardiovascular Pharmacotherapy, Oxford University Press."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.critrevonc.2003.04.004","article-title":"Understanding and preventing drug interactions in elderly patients","volume":"48","author":"Delafuente","year":"2003","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Frisullo, G., Profice, P., Brunetti, V., Scala, I., Bellavia, S., Broccolini, A., Caliandro, P., Iorio, R.D., Morosetti, R., and Pilato, F. (2021). Prospective observational study of safety of early treatment with edoxaban in patients with ischemic stroke and atrial fibrillation (SATES study). Brain Sci., 11.","DOI":"10.3390\/brainsci11010030"},{"key":"ref_11","first-page":"475","article-title":"Warfarin: An evidence-based review of food and drug interactions","volume":"24","author":"Lima","year":"2008","journal-title":"Port. J. Gen. Pract."},{"key":"ref_12","first-page":"170","article-title":"Antithrombotic Therapy: Current and Under Development","volume":"12","author":"Afonso","year":"2016","journal-title":"Angiol. Vasc. Surg."},{"key":"ref_13","unstructured":"Furtado, C., and Silva, A. (2024, September 30). Anticoagulants 2000\u20132013. Published Online 2014. Available online: https:\/\/www.infarmed.pt\/documents\/15786\/17838\/Relatorio_Anticoagulantes_05012015.pdf\/c8c00f82-0541-4bcf-9eb2-80db9f569f99."},{"key":"ref_14","unstructured":"Correia, A., Costa, I., and Caldeira, S. (2024, September 30). Oral Anticoagulants\u2014Usage and Expenditure. Published 2019. Available online: https:\/\/www.infarmed.pt\/documents\/15786\/2713015\/Anticoagulantes+Orais+-+Utiliza\u00e7\u00e3o+e+Despesa\/01c3bd05-9002-43e8-ac54-eec12791ff90."},{"key":"ref_15","first-page":"9","article-title":"Atualiza\u00e7\u00f5es em Coagula\u00e7\u00e3o: Os Anticoagulantes Orais N\u00e3o Antagonistas da Vitamina K (NOACs)","volume":"10","author":"Figueiredo","year":"2018","journal-title":"Rev. Port. Farmacoter."},{"key":"ref_16","unstructured":"Fernandes, M., Manuel, M., and Martinez, J. (2024, July 16). Direct Oral Anticoagulants. Boletim CIM. Published 2018. Available online: https:\/\/www.ordemfarmaceuticos.pt\/fotos\/publicacoes\/boletimcim_out_dez_2018_online_15881267745c51cf9600571.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","article-title":"Drug-drug interactions in an era of multiple anticoagulants: A focus on clinically relevant drug interactions","volume":"132","author":"Vazquez","year":"2018","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: Food, herbal medicines and drug interactions","volume":"31","author":"Frigerio","year":"2017","journal-title":"Blood Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Leite, P.M., Martins, M.A.P., Carvalho, M.d.G., and Castilho, R.O. (2021). Mechanisms and interactions in concomitant use of herbs and warfarin therapy: An updated review. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112103"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bcp.14404","article-title":"Warfarin and food, herbal or dietary supplement interactions: A systematic review","volume":"87","author":"Tan","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Grze\u015bk, G., Rogowicz, D., Wo\u0142owiec, \u0141., Ratajczak, A., Gilewski, W., Chudzi\u0144ska, M., Sinkiewicz, A., and Banach, J. (2021). The clinical significance of drug-food interactions of direct oral anticoagulants. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168531"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Fuentes, A., Rivera-Caravaca, J.M., L\u00f3pez-G\u00e1lvez, R., Mar\u00edn, F., and Rold\u00e1n, V. (2022). Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.787235"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ge, B., Zhang, Z., and Zuo, Z. (2014). Updates on the clinical evidenced herb-warfarin interactions. Evid. Based Complement. Altern. Med., 2014.","DOI":"10.1155\/2014\/957362"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sikorska, J., and Uprichard, J. (2017). Direct oral anticoagulants: A quick guide. Eur. Cardiol. Rev., 12.","DOI":"10.15420\/ecr.2017:11:2"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1111\/bcp.14833","article-title":"Drug-drug interactions with warfarin: A systematic review and meta-analysis","volume":"87","author":"Wang","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Vranckx, P., Valgimigli, M., and Heidbuchel, H. (2018). The significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythmia Electrophysiol. Rev., 7.","DOI":"10.15420\/aer.2017.50.1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_29","unstructured":"Vilares, C., Pereira, C., and Martins, M. (2017). Anticoagulantes Orais\u2014N\u00e3o Antagonistas da vitamina K (NOACs)."},{"key":"ref_30","unstructured":"Infarmed, I.P. (2024, July 15). Summary of Product Characteristics-Varfine. Published 2023. Available online: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/detalhes-medicamento.xhtml."},{"key":"ref_31","unstructured":"European Medicines Agency (2024, July 16). Summary of Product Characteristics-Lixiana. Published 2022. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lixiana-epar-product-information_pt.pdf."},{"key":"ref_32","unstructured":"(2024, July 17). Drug Interaction Checker-For Drugs, Food, and Alcohol. Published 2024. Available online: https:\/\/www.drugs.com\/drug_interactions.html."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","article-title":"Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor","volume":"13","author":"Mendell","year":"2013","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mar, P.L., Gopinathannair, R., Gengler, B.E., Chung, M.K., Perez, A., Dukes, J., Ezekowitz, M.D., Lakkireddy, D., Lip, G.Y.H., and Miletello, M. (2022). Drug Interactions Affecting Oral Anticoagulant Use. Circ. Arrhythmia Electrophysiol., 15.","DOI":"10.1161\/CIRCEP.121.007956"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1389200218666170518165443","article-title":"Rivaroxaban-Metabolism, Pharmacologic Properties and Drug Interactions","volume":"18","author":"Kvasnicka","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s40265-020-01328-6","article-title":"Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice","volume":"80","author":"Corsini","year":"2020","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ferri, N., Colombo, E., Tenconi, M., Baldessin, L., and Corsini, A. (2022). Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061120"},{"key":"ref_39","first-page":"392","article-title":"Anticoagulant effects of statins and their clinical implications","volume":"111","author":"Undas","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_41","unstructured":"European Medicines Agency (2024, July 16). Summary of Product Characteristics-Pradaxa. Published 2022. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_pt.pdf."},{"key":"ref_42","first-page":"30","article-title":"Inova\u00e7\u00e3o Na Terap\u00eautica Anticoagulante","volume":"5","author":"Ramos","year":"2013","journal-title":"Rev. Port. Farmacoter."},{"key":"ref_43","unstructured":"European Medicines Agency (2024, July 16). Summary of Product Characteristics-Xarelto. Published 2022. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_pt.pdf."},{"key":"ref_44","unstructured":"European Medicines Agency (2024, July 16). Summary of Product Characteristics-Eliquis. Published 2022. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_pt.pdf."},{"key":"ref_45","unstructured":"Shikdar, S., Vashisht, R., and Bhattacharya, P.T. (2024, October 23). International Normalized Ratio (INR), StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507707\/."},{"key":"ref_46","unstructured":"Campos, M.d.G., Costa, M.L., and Falc\u00e3o, A. (2024, July 06). Interven\u00e7\u00e3o Farmac\u00eautica na Determina\u00e7\u00e3o de Intera\u00e7\u00f5es Planta-Medicamento. Boletim CIM. Published 2012. Available online: https:\/\/www.ordemfarmaceuticos.pt\/fotos\/publicacoes\/bc.103_importancia_da_farmacogenomica_medicamentos_orfaos_int.farm._na_determinacao_de_inter._planta_medicamento_16324747125a12ef2ad9b11.pdf."},{"key":"ref_47","unstructured":"Gamboa, A., Severiano, A., Martins, A.S., Mousinho, C., Bragan\u00e7a, F., Hergy, F., Pedro, M., Silva, M., Catal\u00e3o, P., and Duarte, S. (2024, July 17). Boletim De Farmacovigil\u00e2ncia Volume 24; N\u00famero 11. Published Online 2020. Available online: https:\/\/www.infarmed.pt\/documents\/15786\/3591914\/Boletim+de+Farmacovigil\u00e2ncia%2C+Volume+24%2C+no11%2C+novembro+de+2020\/ab8e3344-835e-34a3-420d-174cfc835e19."},{"key":"ref_48","unstructured":"(2024, July 18). OIPM\u2014Observat\u00f3rio de Intera\u00e7\u00f5es Planta-Medicamento. Available online: https:\/\/oipm.uc.pt\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ptr.5591","article-title":"A Critical Approach to Evaluating Clinical Efficacy, Adverse Events and Drug Interactions of Herbal Remedies","volume":"30","author":"Izzo","year":"2016","journal-title":"Phyther. Res."},{"key":"ref_50","unstructured":"Gamboa, A., Severiano, A., Martins, A.S., Mousinho, C., Bragan\u00e7a, F., Hergy, F., Pedro, M., Silva, M., Catal\u00e3o, P., and Duarte, S. (2024, July 18). Boletim De Farmacovigil\u00e2ncia Volume 24; N\u00famero 3. Published 2020. Available online: https:\/\/www.infarmed.pt\/documents\/15786\/3591914\/Boletim+de+Farmacovigil\u00e2ncia%2C+Volume+24%2C+no3%2C+mar\u00e7o+de+202\/62d0a9c0-a579-8b7b-ec9e-c1ea975c412a?version=1.3."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2125.2010.03620.x","article-title":"Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects","volume":"69","author":"Abdul","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.thromres.2020.08.016","article-title":"Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review","volume":"194","author":"Li","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mili\u0107, N., Milo\u0161ev\u00edc, N., Goloe\u00f2rbin Kon, S., Boz\u01d0\u0107, T., Abenavoli, L., and Borrelli, F. (2014). Warfarin interactions with medicinal herbs. Nat. Prod. Commun., 9.","DOI":"10.1177\/1934578X1400900835"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","article-title":"Drug and dietary interactions of warfarin and novel oral anticoagulants: An update","volume":"31","author":"Nutescu","year":"2011","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1345\/aph.19029","article-title":"Interaction between warfarin and danshen (Salvia miltiorrhiza)","volume":"35","author":"Chan","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Karatoprak, G.S. (2019). Horse Chestnut. Nonvitam. Nonmineral Nutr. Suppl., 295\u2013299.","DOI":"10.1016\/B978-0-12-812491-8.00042-4"},{"key":"ref_57","unstructured":"Bilberry (2024, September 30). LiverTox Clin. Res. Inf. Drug-Induced Liver Inj. Published Online 20 February 2019, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548250\/."},{"key":"ref_58","unstructured":"Karimpour-Reihan, S., Firuzei, E., Khosravi, M., and Abbaszade, M. (2018). Coagulation Disorder following Red Clover (Trifolium pratense) Misuse: A Case Report. Adv. J. Emerg. Med., 2."},{"key":"ref_59","first-page":"135","article-title":"The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"124","author":"Grymonprez","year":"2023","journal-title":"Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"758","DOI":"10.5603\/CJ.a2021.0088","article-title":"Pharmacotherapy of atrial fibrillatioin COVID-19 patients","volume":"28","author":"Jaguszewski","year":"2021","journal-title":"Cardiol. J."}],"container-title":["Scientia Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-0532\/93\/3\/35\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:19:23Z","timestamp":1760033963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-0532\/93\/3\/35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["scipharm93030035"],"URL":"https:\/\/doi.org\/10.3390\/scipharm93030035","relation":{},"ISSN":["2218-0532"],"issn-type":[{"value":"2218-0532","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}